203 related articles for article (PubMed ID: 28189679)
1. SOX10 induced Nestin expression regulates cancer stem cell properties of TNBC cells.
Feng W; Liu S; Zhu R; Li B; Zhu Z; Yang J; Song C
Biochem Biophys Res Commun; 2017 Apr; 485(2):522-528. PubMed ID: 28189679
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
3. Nestin positively regulates the Wnt/β-catenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells.
Zhao Z; Lu P; Zhang H; Xu H; Gao N; Li M; Liu C
Breast Cancer Res; 2014 Jul; 16(4):408. PubMed ID: 25056574
[TBL] [Abstract][Full Text] [Related]
4. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
5. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
6. Schlafen12 Reduces the Aggressiveness of Triple Negative Breast Cancer through Post-Transcriptional Regulation of ZEB1 That Drives Stem Cell Differentiation.
Al-Marsoummi S; Vomhof-DeKrey E; Basson MD
Cell Physiol Biochem; 2019; 53(6):999-1014. PubMed ID: 31838790
[TBL] [Abstract][Full Text] [Related]
7. The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer.
Doherty MR; Parvani JG; Tamagno I; Junk DJ; Bryson BL; Cheon HJ; Stark GR; Jackson MW
Breast Cancer Res; 2019 Apr; 21(1):54. PubMed ID: 31036052
[TBL] [Abstract][Full Text] [Related]
8. IMP3 promotes TNBC stem cell property through miRNA-34a regulation.
Huang QD; Zheng SR; Cai YJ; Chen DL; Shen YY; Lin CQ; Hu XQ; Wang XH; Shi H; Guo GL
Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2688-2696. PubMed ID: 29771420
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Sonic Hedgehog Signaling Pathway by Thiazole Antibiotic Thiostrepton Attenuates the CD44+/CD24-Stem-Like Population and Sphere-Forming Capacity in Triple-Negative Breast Cancer.
Yang N; Zhou TC; Lei XX; Wang C; Yan M; Wang ZF; Liu W; Wang J; Ming KH; Wang BC; Xu BL; Liu Q
Cell Physiol Biochem; 2016; 38(3):1157-70. PubMed ID: 26963129
[TBL] [Abstract][Full Text] [Related]
10. MiR-27a modulates radiosensitivity of triple-negative breast cancer (TNBC) cells by targeting CDC27.
Ren YQ; Fu F; Han J
Med Sci Monit; 2015 May; 21():1297-303. PubMed ID: 25943633
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of epithelial–mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer.
Pomp V; Leo C; Mauracher A; Korol D; Guo W; Varga Z
Breast Cancer Res Treat; 2015 Nov; 154(1):45-55. PubMed ID: 26467042
[TBL] [Abstract][Full Text] [Related]
12. c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun.
Xie X; Kaoud TS; Edupuganti R; Zhang T; Kogawa T; Zhao Y; Chauhan GB; Giannoukos DN; Qi Y; Tripathy D; Wang J; Gray NS; Dalby KN; Bartholomeusz C; Ueno NT
Oncogene; 2017 May; 36(18):2599-2608. PubMed ID: 27941886
[TBL] [Abstract][Full Text] [Related]
13. MiR-4319 Suppress the Malignancy of Triple-Negative Breast Cancer by Regulating Self-Renewal and Tumorigenesis of Stem Cells.
Chu J; Li Y; Fan X; Ma J; Li J; Lu G; Zhang Y; Huang Y; Li W; Huang X; Fu Z; Yin Y; Yuan H
Cell Physiol Biochem; 2018; 48(2):593-604. PubMed ID: 30021199
[TBL] [Abstract][Full Text] [Related]
14. Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.
Fonseca NA; Rodrigues AS; Rodrigues-Santos P; Alves V; Gregório AC; Valério-Fernandes Â; Gomes-da-Silva LC; Rosa MS; Moura V; Ramalho-Santos J; Simões S; Moreira JN
Biomaterials; 2015 Nov; 69():76-88. PubMed ID: 26283155
[TBL] [Abstract][Full Text] [Related]
15. Obesity-induced MBD2_v2 expression promotes tumor-initiating triple-negative breast cancer stem cells.
Teslow EA; Mitrea C; Bao B; Mohammad RM; Polin LA; Dyson G; Purrington KS; Bollig-Fischer A
Mol Oncol; 2019 Apr; 13(4):894-908. PubMed ID: 30636104
[TBL] [Abstract][Full Text] [Related]
16. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
[TBL] [Abstract][Full Text] [Related]
17. Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC).
Ma F; Li H; Wang H; Shi X; Fan Y; Ding X; Lin C; Zhan Q; Qian H; Xu B
Cancer Lett; 2014 Oct; 353(2):153-9. PubMed ID: 25130168
[TBL] [Abstract][Full Text] [Related]
18. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer.
Kagara N; Huynh KT; Kuo C; Okano H; Sim MS; Elashoff D; Chong K; Giuliano AE; Hoon DS
Am J Pathol; 2012 Jul; 181(1):257-67. PubMed ID: 22626806
[TBL] [Abstract][Full Text] [Related]
20. Jagged2 promotes cancer stem cell properties of triple negative breast cancer cells and paclitaxel resistance via regulating microRNA-200.
Li CY; Miao KL; Chen Y; Liu LY; Zhao GB; Lin MH; Jiang C
Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):6008-6014. PubMed ID: 30280784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]